The genomic landscape of response to EGFR blockade in colorectal cancer

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies

(2015) Eugenia R. Zanella et al.   Science Translational Medicine

Personalized genomic analyses for cancer mutation discovery and interpretation

(2015) Siân Jones et al.   Science Translational Medicine

HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment

(2015) S. M. Kavuri et al.   Cancer Discovery

Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA

(2015) Luis A. Diaz et al.   Oncotarget

Functional Dissection of the Epidermal Growth Factor Receptor Epitopes Targeted by Panitumumab and Cetuximab

(2015) Mareike Voigt et al.   NEOPLASIA

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2014) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer

(2014) S. Misale et al.   Science Translational Medicine

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

(2014) C. Bettegowda et al.   Science Translational Medicine

Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)

(2013) A. Pavlicek et al.   MOLECULAR CANCER THERAPEUTICS

Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas

(2013) Yuchen Jiao et al.   NATURE GENETICS

Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer

(2013) Salvatore Siena et al.   PLoS One

Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer

(2013) Alberto Bardelli et al.   Cancer Discovery

LAS: A Software Platform to Support Oncological Data Management

(2012) Elena Baralis et al.   JOURNAL OF MEDICAL SYSTEMS

Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor

(2012) Klaus Koefoed et al.   mAbs

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

(2012) Clara Montagut et al.   NATURE MEDICINE

Fibroblast growth factors and their receptors in cancer

(2011) Jørgen Wesche et al.   BIOCHEMICAL JOURNAL

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer

(2011) A Ålgars et al.   BRITISH JOURNAL OF CANCER

Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic Correlations

(2011) F. Galimi et al.   CLINICAL CANCER RESEARCH

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

(2011) K. Yonesaka et al.   Science Translational Medicine

A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer

(2011) A. Bertotti et al.   Cancer Discovery

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab

(2010) Jolien Tol et al.   EUROPEAN JOURNAL OF CANCER

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Diverse somatic mutation patterns and pathway alterations in human cancers

(2010) Zhengyan Kan et al.   NATURE

PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

(2009) A. Sartore-Bianchi et al.   CANCER RESEARCH

Novel MEK1 Mutation Identified by Mutational Analysis of Epidermal Growth Factor Receptor Signaling Pathway Genes in Lung Adenocarcinoma

(2008) J. L. Marks et al.   CANCER RESEARCH

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparative lesion sequencing provides insights into tumor evolution

(2008) S. Jones et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers

(2008) R. J. Leary et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA